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Dog bites are a major source of morbidity and mortality worldwide, 
accounting for up to 1.5% of all visits to emergency medicine units 
(EMUs).1 They represent an even higher financial and disease burden 
in rabies-endemic areas such as KwaZulu-Natal (KZN),2 because 
expensive post-exposure prophylaxis, which represents a significant 
proportion of EMUs’ annual drugs budget, must be administered to 
many bite victims. Since rabies is almost universally fatal, its control 
is of paramount importance in endemic areas.
Around 10 - 30 human cases of rabies are confirmed each year 
in South Africa, and result almost exclusively from dogs biting 
humans.2 A current programme funded by the Bill and Melinda 
Gates Foundation, that aims to eradicate rabies in South Africa 
and worldwide, uses dog vaccination and animal contact tracing to 
prevent dog-to-dog transmission. Yet little is known about dog-to-
human transmission.3 Since targeted rabies eradication programmes 
to prevent dog-to-human transmission may be strategically viable 
in KZN, understanding the demographics of dog bites plays an 
important role in understanding and controlling the transmission 
of the virus. 
Immunocompromised patients may present with atypical rabies. 
Only one paper has been published on this subject, in which a 
patient in Mali presented atypically with encephalitis following a 
dog bite.4 Therefore in areas such as KZN, where HIV is epidemic, 
high diagnostic suspicion for rabies is needed when dealing with 
the demographic groups who are more likely to have sustained dog 
bites.
Internationally, dog bites are graded as 1, 2 or 3, depending 
on severity (Table 1). This grading is important because it guides 
therapy: only grade 3 bites require immunoglobulin; only grade 2 or 
3 bites require vaccine; and grade 1 bites require no treatment. 
Administration of rabies vaccine alone is unlikely to have any effect 
on disease progression if the rabies virus has been transmitted in the 
bite. This can only be prevented through the use of immunoglobulin, 
which is effective against the rabies virus for the first 10 days after 
exposure. Anecdotally, up to a third of emergency department 
drug budgets may be spent on rabies immunoglobulin. An average 
adult’s administered immunoglobulin costs R2 122, representing a 
significant financial burden, which could be minimised by targeting 
therapy only to those at risk. 
Internationally, few publications examine the demographics of dog 
bites, and none looks at their management. Publications suggest that 
dog bites are most prevalent in children between the ages of 1 and 9 
years, but no studies consider sex differences in adults, or are specific 
to the population of KZN.1, 5
A study examining the demographics of dog-bite victims in KZN 
is important, as it will inform clinicians about which patient groups 
must be treated with a high diagnostic suspicion for rabies; inform 
and refine the rabies eradication programme; and highlight the cost 
of immunoglobulin and when best to use it.
Therefore, we studied the demographics and treatment of dog-bite 
victims presenting to a tertiary referral centre in northern KZN.
Methods
Records were maintained for all dog-bite victims presenting to the 
EMU at Ngwelezane Hospital, the main referral hospital for northern 
KZN, between August 2007 and September 2011. For each instance 
of dog bite, information recorded included age (in years), sex, home 
location, and clinical information including grade of dog bite and 
treatment given. The grade was determined using the common scale 
of rabies exposure (Fig. 1).2 
Treatment given was (i) advice only; (ii) rabies vaccine; or (iii) rabies 
vaccine with rabies immunoglobulin. The number of doses of vaccine 
administered was incompletely recorded and often given at peripheral 
clinics, and is therefore not included in the final analysis. Treatment 
was guided by the South African guidelines (Fig. 1). Records were 
maintained in a paper ledger in the EMU. For our study, each instance 
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was entered onto a prospectively maintained database on a password-
protected computer using Microsoft Excel, and analysed using the 
same programme. Analysis was carried out using simple descriptive 
statistics. Records were maintained and analysed in accordance with 
local policy on patient confidentiality and consent.
All information relating to the cost of immunoglobulin was taken 
from the hospital pharmacy computer system.
The Ngwelezane Hospital ethics committee approved the study.
Results
Between August 2007 and September 2011, a total of 821 patients 
presented to Ngwelezane Hospital complaining of dog bites. Of these, 
458 (55.8%) patients were male, and ages ranged between 0 and 86 
years old. Sex was not recorded for 2 patients.
The average age of patients presenting with dog bites was 25 
years, and the most common age was 10 years (19 patients). The 
most common age group to present with dog-bite injuries was age 
6 - 10 (148 patients). Younger males were bitten more commonly 
than younger females, although females >40 years were bitten more 
commonly than males in the same age group. 
Of the 821 bites, 642 (78%) were grade 3; 84 (10%) were grade 2; 
and 43 (5%) were grade 1. In 52 cases (7%), grade of bite was not 
recorded.Treatment with rabies vaccine was started in 90% of cases of 
grade 1 bites, 97% of grade 2 bites and 99% of grade 3 bites (Fig. 2). 
Immunoglobulin was administered for 53% of grade 1 bites, 84% of 
grade 2 bites and 82% of grade 3 bites.
The total cost of treatment with Rabigam (rabies immmunoglobulin) 
was R802 767, for 461 120 international units (IU) of rabies 
immunoglobulin at R530 for 300 IU. Of this total cost, R640 487 was 
spent on grade 3 bites and R162 279 on grade 1 and 2 bites. 
Discussion
A prospectively maintained database was used to demonstrate 
the demographic features and treatment administered to patients 
presenting with dog bites to a tertiary referral centre in northern KZN. 
Males present more frequently than females, and young males (ages 
6 - 10) are most likely to present. This trend reverses after the age of 
40 years, when females are more likely to present than males. We also 
showed that 99% of grade 3 bite patients are treated with rabies vaccine, 
but the rate of treatment with immunoglobulin is lower (82%). 
Our results agree with the other large South African study of dog-
bite demographics,5 that suggests that the most common age group 
to present with dog bites is 4 - 7 years, with a mean of 6.84 years. 
Table 1. Clinical presentation and treatment of dog bites (adapted from reference 2)
Risk category Type of exposure Action to be taken
1 Touching/feeding animal
Licking of intact skin
None 
2 Nibbling of uncovered skin 
Superficial scratch without bleeding
Licking of broken skin
Give vaccine 
Do not give anti-rabies immunoglobulin 
3 Bites/scratches that penetrate the skin and draw 
blood
Licking mucous membranes
Give vaccine 
Give anti-rabies immunoglobulin
Fig 1. Age and sex diﬀ erences in dog-bite patients.
Fig. 2. Treatment of dog bites stratifi ed by grade of bite.
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Dwyer et al. also found that young male patients are more likely than 
females to present with dog bites. The other large study on dog-bite 
demographics, conducted in Florida, USA, suggests that a younger 
age group (1 - 4 years) presents more commonly.1 
Our results suggest that targeting parents remains the best strategy 
to ensure that dog-bite patients present at hospitals. This is because 
most patients are young (6 - 11) and rely on their parents for 
healthcare and transport. School-based interventions may also be 
viable, but this may be less effective because northern KZN’s 
population is rural and school attendance is relatively low.6 
In immunocompromised patients who are bitten by a rabid animal 
and do not present to hospital, subsequent development of rabies 
may go unnoticed or be treated as HIV-associated encephalitis or 
meningitis. Therefore high levels of suspicion for rabies are advisable 
in all immuncompromised individuals presenting with neurological 
symptoms. The rabies virus can be tested for by using PCR on buccal 
swabs; this is an important measure to identify outbreaks of rabies 
which might otherwise go unnoticed. 
Rabies vaccine is administered to patients presenting with dog 
bites in a high rate of cases. Grade 1 dog bites need no treatment,2 
yet 90% of these patients received vaccination and 53% received 
immunoglobulin. As immunoglobulin is expensive, its use should 
be reserved for patients with higher-risk bites. Further education 
on the risk stratification of dog bites could help to rectify this over-
treatment, and decrease spending on immunoglobulin. 
Patients with grade 3 bites should be given immunoglobulin. In 
these cases, vaccine should be initiated on the first visit to hospital 
and only discontinued if the dog remains healthy after 10 days, or 
if laboratory samples confirm that the animal does not have rabies. 
However, only 82% of our patients with grade 3 bites received 
immunoglobulin. Possible reasons for this include: 
• If the dog is known to the patient, is known to be vaccinated, 
and is healthy, then at Ngwelezane Hospital immunoglobulin 
is not administered as the risk of transmission is judged to be 
extremely low.
• Since there were no cases of rabies in our cohort, or at the 
hospital during our study period, or indeed in the whole of South 
Africa in 2009,7 healthcare providers may be complacent about 
the importance of immunoglobulin and vaccine administration 
in grade 3 bites. 
• It is possible that the recording of grade of bite was inaccurate, 
and that many of the bites did not require immunoglobulin. 
Over the three-year study period, immunoglobulin costing over 
R160 000 was administered to dog-bite victims who did not require 
it. This represents a potential cost saving of around 25%. Rabies 
immunoglobulin is the 9th most expensive drug purchased by our 
hospital (after antiretrovirals, insulin and plasma products) and 
reducing its use would represent a welcome saving. 
The limitations of this study primarily relate to the maintenance of 
the database.  Bites are recorded by EMU nurses and doctors, who see 
and treat the dog-bite patients, in a paper ledger stored in the EMU. 
Therefore some cases may be incompletely recorded or not recorded, 
as is seen in the 7% of cases for which grade of bite is not recorded. 
New staff, who may not be adequately inducted into the EMU, may 
be particularly prone to this. The grading system for bites is also open 
to interpretative error, although this is minimised by displaying the 
grading system on the wall of the EMU. 
Many cases of dog bite will never present to the EMU and will 
be managed in the community with traditional treatments or no 
treatment. This is particularly the case for grade 1 and 2 exposures, 
which are usually not perceived to be a risk to health. This may be 
why we record so few cases of grade 1 and 2 exposures, even though 
these must occur more frequently than grade 3 exposures. 
Repeated dosing of vaccine is also recorded incompletely in 
many cases. This is because dosing is often initiated or continued 
at peripheral clinics. Therefore we did not analyse information 
pertaining to the number of doses of vaccine patients received. 
Educating EMU staff about the importance of recording dog 
bites, the correct grading of bites, and the recommended treatment 
modalities would improve patient care. Installing a robust computer 
database to record demographic data would also improve the quality 
of record keeping. If this included a hospital-wide computer network, 
then patient care and follow-up could be vastly improved with 
minimal financial and time investment.
We have shown that dog bites in northern KZN are most likely to 
occur in young males between the ages of 6 and 10 years. Treatment 
with rabies vaccine is almost universal in patients presenting with 
dog bite, but administration of immunoglobulin to patients with 
grade 3 bites is lower than expected. Furthermore, the inappropriate 
use of expensive immunoglobulin in grade 1 and 2 bites places an 
unnecessary burden on the healthcare budget. We wish to emphasise 
the importance of correctly classifying the grade of dog bite and of 
treating with immunoglobulin when necessary, to minimise cost and 
maximise prevention of further cases of rabies in humans.
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